Final Exam: NR 568/ NR568 (New 2025/
2026 Update) Advanced Pharmacology
for the AGPCNP Guide| Questions &
Answers| Grade A| 100% Correct
(Verified Solutions)- Chamberlain
DOMAIN 1: PHARMACOKINETICS & PHARMACODYNAMICS
(Questions 1–20)
1. A 70-year-old patient with heart failure is started on digoxin. Which
age-related change in pharmacokinetics most increases the risk of toxicity?
• A) Decreased hepatic first-pass metabolism
• B) Increased volume of distribution for water-soluble drugs
• C) Decreased renal clearance of digoxin
• D) Enhanced glomerular filtration rate
✅ ,,,ANSWER,,,: C) Decreased renal clearance of digoxin
Rationale: Renal clearance declines significantly with age. Because digoxin is
primarily excreted unchanged by the kidneys, reduced renal function leads to drug
accumulation and increased risk of toxicity. Dose adjustment based on renal
function and monitoring of digoxin levels is essential in older adults.
,2. A patient with a genetic polymorphism resulting in CYP2D6 poor
metabolizer phenotype is prescribed codeine for pain. What is the most likely
outcome?
• A) Increased risk of respiratory depression
• B) Prolonged half-life of codeine but normal analgesia
• C) Increased risk of serotonin syndrome
• D) Little to no analgesic effect
✅ ,,,ANSWER,,,: D) Little to no analgesic effect
Rationale: Codeine is a prodrug that requires conversion by CYP2D6 to its active
metabolite, morphine. Poor metabolizers have little or no enzyme activity,
resulting in minimal morphine formation and therefore inadequate pain relief.
Alternative analgesics not dependent on CYP2D6 metabolism should be used.
3. A patient is receiving a drug that is a weak base (pKa 8.5). Which of the
following would increase its renal excretion?
• A) Increasing urine flow rate only
• B) Alkalinizing the urine (increasing pH)
• C) Acidifying the urine (decreasing pH)
• D) Administering with a high-fat meal
✅ ,,,ANSWER,,,: C) Acidifying the urine (decreasing pH)
Rationale: Weak bases are more ionized in acidic environments. In an acidic urine
pH, the weak base becomes ionized and is “trapped” in the urine, preventing
reabsorption and enhancing elimination. Alkalinization would increase the
non-ionized form, favoring reabsorption and decreasing excretion.
4. A patient with hypoalbuminemia (low serum albumin) is prescribed a
highly protein-bound drug (e.g., warfarin). What effect do you anticipate?
• A) Decreased drug effect due to increased protein binding
, • B) Increased free drug fraction and risk of toxicity
• C) No change in drug effect
• D) Prolonged time to reach steady state
✅ ,,,ANSWER,,,: B) Increased free drug fraction and risk of toxicity
Rationale: Only unbound (free) drug is pharmacologically active.
Hypoalbuminemia reduces available protein-binding sites, increasing the free
fraction of highly protein-bound drugs. This can lead to toxicity at standard doses.
Dose reduction may be required, and therapeutic drug monitoring is
recommended.
5. A drug has a half-life of 24 hours. Approximately how long will it take to
reach steady state after starting a fixed daily dose?
• A) 2 days
• B) 5 days
• C) 10 days
• D) 2 weeks
✅ ,,,ANSWER,,,: B) 5 days
Rationale: Steady state is achieved after approximately 4-5 half-lives of regular
dosing. With a 24-hour half-life, steady state is reached in about 4-5 days (96-120
hours). This principle is used to determine when therapeutic drug levels can be
expected after initiating or changing a medication.
6. Which cytochrome P450 enzyme is responsible for metabolizing
approximately 50% of all drugs and is most commonly involved in drug-drug
interactions?
• A) CYP1A2
• B) CYP2C9
• C) CYP2D6
• D) CYP3A4
, ✅ ,,,ANSWER,,,: D) CYP3A4
Rationale: CYP3A4 metabolizes >50% of all drugs, making it the most frequent
source of clinically significant drug interactions. Common substrates include
statins, calcium channel blockers, benzodiazepines, and immunosuppressants.
Strong CYP3A4 inhibitors (e.g., ketoconazole, grapefruit juice) increase levels of
these drugs, while inducers (e.g., rifampin) decrease levels.
7. A patient with liver cirrhosis is prescribed a medication with high first-pass
metabolism (e.g., propranolol). What pharmacokinetic change is expected?
• A) Decreased bioavailability
• B) Increased oral bioavailability
• C) Decreased half-life
• D) No change in bioavailability
✅ ,,,ANSWER,,,: B) Increased oral bioavailability
Rationale: First-pass metabolism occurs in the liver. Liver cirrhosis impairs
hepatic function, reducing first-pass extraction and resulting in higher oral
bioavailability. The patient may require a lower oral dose to avoid toxicity. This is
clinically relevant for drugs like propranolol, morphine, and verapamil.
8. Which of the following would be most appropriate for monitoring a drug
with a narrow therapeutic index?
• A) Monitoring only for clinical signs of toxicity
• B) Periodic measurement of serum drug concentrations
• C) Increasing the dose until adverse effects occur
• D) Using the drug only intravenously
✅ ,,,ANSWER,,,: B) Periodic measurement of serum drug concentrations
Rationale: Narrow therapeutic index (NTI) drugs have a small margin between
therapeutic and toxic doses. Therapeutic drug monitoring (TDM) of serum
concentrations is essential to maintain levels within the therapeutic window and
2026 Update) Advanced Pharmacology
for the AGPCNP Guide| Questions &
Answers| Grade A| 100% Correct
(Verified Solutions)- Chamberlain
DOMAIN 1: PHARMACOKINETICS & PHARMACODYNAMICS
(Questions 1–20)
1. A 70-year-old patient with heart failure is started on digoxin. Which
age-related change in pharmacokinetics most increases the risk of toxicity?
• A) Decreased hepatic first-pass metabolism
• B) Increased volume of distribution for water-soluble drugs
• C) Decreased renal clearance of digoxin
• D) Enhanced glomerular filtration rate
✅ ,,,ANSWER,,,: C) Decreased renal clearance of digoxin
Rationale: Renal clearance declines significantly with age. Because digoxin is
primarily excreted unchanged by the kidneys, reduced renal function leads to drug
accumulation and increased risk of toxicity. Dose adjustment based on renal
function and monitoring of digoxin levels is essential in older adults.
,2. A patient with a genetic polymorphism resulting in CYP2D6 poor
metabolizer phenotype is prescribed codeine for pain. What is the most likely
outcome?
• A) Increased risk of respiratory depression
• B) Prolonged half-life of codeine but normal analgesia
• C) Increased risk of serotonin syndrome
• D) Little to no analgesic effect
✅ ,,,ANSWER,,,: D) Little to no analgesic effect
Rationale: Codeine is a prodrug that requires conversion by CYP2D6 to its active
metabolite, morphine. Poor metabolizers have little or no enzyme activity,
resulting in minimal morphine formation and therefore inadequate pain relief.
Alternative analgesics not dependent on CYP2D6 metabolism should be used.
3. A patient is receiving a drug that is a weak base (pKa 8.5). Which of the
following would increase its renal excretion?
• A) Increasing urine flow rate only
• B) Alkalinizing the urine (increasing pH)
• C) Acidifying the urine (decreasing pH)
• D) Administering with a high-fat meal
✅ ,,,ANSWER,,,: C) Acidifying the urine (decreasing pH)
Rationale: Weak bases are more ionized in acidic environments. In an acidic urine
pH, the weak base becomes ionized and is “trapped” in the urine, preventing
reabsorption and enhancing elimination. Alkalinization would increase the
non-ionized form, favoring reabsorption and decreasing excretion.
4. A patient with hypoalbuminemia (low serum albumin) is prescribed a
highly protein-bound drug (e.g., warfarin). What effect do you anticipate?
• A) Decreased drug effect due to increased protein binding
, • B) Increased free drug fraction and risk of toxicity
• C) No change in drug effect
• D) Prolonged time to reach steady state
✅ ,,,ANSWER,,,: B) Increased free drug fraction and risk of toxicity
Rationale: Only unbound (free) drug is pharmacologically active.
Hypoalbuminemia reduces available protein-binding sites, increasing the free
fraction of highly protein-bound drugs. This can lead to toxicity at standard doses.
Dose reduction may be required, and therapeutic drug monitoring is
recommended.
5. A drug has a half-life of 24 hours. Approximately how long will it take to
reach steady state after starting a fixed daily dose?
• A) 2 days
• B) 5 days
• C) 10 days
• D) 2 weeks
✅ ,,,ANSWER,,,: B) 5 days
Rationale: Steady state is achieved after approximately 4-5 half-lives of regular
dosing. With a 24-hour half-life, steady state is reached in about 4-5 days (96-120
hours). This principle is used to determine when therapeutic drug levels can be
expected after initiating or changing a medication.
6. Which cytochrome P450 enzyme is responsible for metabolizing
approximately 50% of all drugs and is most commonly involved in drug-drug
interactions?
• A) CYP1A2
• B) CYP2C9
• C) CYP2D6
• D) CYP3A4
, ✅ ,,,ANSWER,,,: D) CYP3A4
Rationale: CYP3A4 metabolizes >50% of all drugs, making it the most frequent
source of clinically significant drug interactions. Common substrates include
statins, calcium channel blockers, benzodiazepines, and immunosuppressants.
Strong CYP3A4 inhibitors (e.g., ketoconazole, grapefruit juice) increase levels of
these drugs, while inducers (e.g., rifampin) decrease levels.
7. A patient with liver cirrhosis is prescribed a medication with high first-pass
metabolism (e.g., propranolol). What pharmacokinetic change is expected?
• A) Decreased bioavailability
• B) Increased oral bioavailability
• C) Decreased half-life
• D) No change in bioavailability
✅ ,,,ANSWER,,,: B) Increased oral bioavailability
Rationale: First-pass metabolism occurs in the liver. Liver cirrhosis impairs
hepatic function, reducing first-pass extraction and resulting in higher oral
bioavailability. The patient may require a lower oral dose to avoid toxicity. This is
clinically relevant for drugs like propranolol, morphine, and verapamil.
8. Which of the following would be most appropriate for monitoring a drug
with a narrow therapeutic index?
• A) Monitoring only for clinical signs of toxicity
• B) Periodic measurement of serum drug concentrations
• C) Increasing the dose until adverse effects occur
• D) Using the drug only intravenously
✅ ,,,ANSWER,,,: B) Periodic measurement of serum drug concentrations
Rationale: Narrow therapeutic index (NTI) drugs have a small margin between
therapeutic and toxic doses. Therapeutic drug monitoring (TDM) of serum
concentrations is essential to maintain levels within the therapeutic window and
